DS1025 / Daiichi Sankyo - LARVOL DELTA

DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo (Businesswire) - "The first patient has been dosed in a first-in-human phase 1 trial evaluating DS1025 in adult patients with advanced or metastatic solid tumors with disease progression on or after at least one prior line of standard therapy....The trial is expected to enroll up to 45 patients across multiple sites in Asia and Europe."

First-in-human • Trial status • Solid Tumor

First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Daiichi Sankyo | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor

First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=45 | Not yet recruiting | Sponsor: Daiichi Sankyo

First-in-human • New P1 trial • Oncology • Solid Tumor